DUB Therapeutics
DUB Therapeutics is developing a proprietary self-delivering siRNA (sdRNA) platform to treat fibrotic diseases, starting with ocular surface conditions that cause corneal scarring and vision loss. Its lead candidate, DUB-001, is a non-invasive liquid eye drop that penetrates corneal cells without injections or delivery carriers, providing therapeutic benefit for over 90 days from a single dose. The company is advancing DUB-001 through preclinical development with Phase 1 clinical trials planned for 2027.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
- Hardware
- Medical Devices
Funding
Founders
Founder details are not available yet.
Product
Problem
Fibrotic diseases, particularly ocular surface conditions, lead to tissue scarring that impairs vision and can result in blindness. Current treatments rely on frequent steroid dosing, expensive nerve growth factor therapies, or invasive surgical transplants, all of which have significant limitations in efficacy, accessibility, and patient adherence. There is a critical unmet need for a non-invasive, long-lasting, and affordable anti-fibrotic therapy.
Solution
DUB Therapeutics has developed a proprietary self-delivering siRNA (sdRNA) platform that targets the root causes of tissue scarring at the genetic level. The lead program, DUB-001, is formulated as a liquid eye drop that penetrates corneal cells without the need for injections, viral vectors, or lipid nanoparticles. A single dose provides therapeutic benefit for more than 90 days in vivo, dramatically reducing the dosing burden compared to current standards of care that require multiple daily applications. The sdRNA molecules are chemically modified to enhance stability and cellular uptake, and the drug product remains stable at room temperature for over 360 days, enabling broad distribution and easy storage. The company is advancing DUB-001 through preclinical development with Phase 1 clinical trials planned to begin enrollment in 2027, targeting corneal scarring and other ocular surface fibrotic conditions.
Target Audience
Primary customers are ophthalmologists and eye care specialists treating patients with corneal scarring and ocular surface fibrotic diseases, along with pharmaceutical partners seeking anti-fibrotic therapeutic options. The broader platform targets dermatologists and specialists managing systemic fibrotic conditions as the pipeline expands.
Features
- Self-delivering siRNA (sdRNA) platform that penetrates cells without AAV vectors, lipid nanoparticles, or other delivery carriers
- Single-dose administration providing therapeutic effect for more than 90 days in vivo
- Room-temperature stable formulation for over 360 days, eliminating cold-chain logistics
- Non-invasive topical delivery as liquid eye drops, avoiding intraocular injections
- Targets novel enzyme pathways that control protein degradation and influence wound healing stages to promote tissue regeneration
- Pipeline expansion across ophthalmology, dermatology, and systemic fibrosis indications
- GLP manufacturing completed for DUB-001 with CRO partnership secured for clinical development